ClinicalTrials.gg
CompletedNCT05039099Updated Sep 30, 2026Results posted

A Study to Evaluate, Safety, Tolerability, and PK of AP-101 in Participants With ALS

A Phase 2 interventional study of AP-101 and Placebo in Amyotrophic Lateral Sclerosis, sponsored by AL-S Pharma. Completed at 13 sites in 6 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-09-30.

Sponsored by AL-S Pharma · Phase 2, Interventional, and Treatment

Updated Sep 30, 2026Results postedStudy documents posted+5 moreGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
73
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 82 studies in Amyotrophic Lateral Sclerosis with a site in Canada — 15 open to participants now, 25 under way, 5 of them phase 3. Amyotrophic Lateral Sclerosis · Canada.

Enrollment
38th of 72
73 · median 75
Started
2021
with 8 others
Phase 2
21 of 82
2 open now
Registered
54th of 82
by date
Lead sponsor
2 of 82
AL-S Pharma

Among the 82 studies in Amyotrophic Lateral Sclerosis with a site in Canada, this one is the 38th largest by enrollment of the 72 interventional ones that give a count, is one of 9 that started in 2021, is one of 21 in phase 2, and was the 54th registered.

Amyotrophic Lateral Sclerosis

980 studies on the registry are indexed under Amyotrophic Lateral Sclerosis; 279 are open to participants now.

Browse Amyotrophic Lateral Sclerosis studies →

Open to participants now

15 of the 82 studies in Amyotrophic Lateral Sclerosis with a site in Canada are open now. Recruiting first, the newest first:

10 more — sign in →

All 15 open studies →

A study can be open while its sites in Canada have not opened yet or have stopped. Only those recruiting at a site in Canada →

Who these studies take

Of the 193 Amyotrophic Lateral Sclerosis studies recruiting now, 118 (61%) set no upper age limit and 23 (12%) stop at 75 or younger; 15 take children under 18; 55 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 82 studies in Amyotrophic Lateral Sclerosis with a site in Canada, or all of them as a file.
02

Study summary

The purpose of this study is to evaluate the safety, tolerability, PK, and PD of AP-101 in participants with fALS and sALS.

Read the detailed description

This Phase 2a, multicenter, randomized, double-blind, placebo-controlled study evaluated the safety, tolerability, pharmacokinetics, and pharmacodynamic markers of AP-101 in adults with sporadic ALS or SOD1-associated ALS. A total of 73 participants were randomized within each ALS cohort in a 2:1 ratio to receive AP-101 or placebo during a 24-week double-blind treatment period.

Participants assigned to AP-101 received a 500 mg intravenous loading dose on Day 1, a 2500 mg intravenous dose on Day 2, and 2500 mg intravenously every 3 weeks beginning on Day 22 through Week 24. Participants assigned to placebo received matching intravenous infusions on the same schedule. Stable use of locally approved ALS treatments was permitted.

Participants who completed the double-blind period could enter an optional 24-week open-label extension in which all participants received AP-101. To maintain the integrity of the double-blind period, the initial dose in the open-label extension remained blinded. Participants were followed for safety and pharmacokinetic assessments for up to 16 weeks after their final study dose.

The primary assessments evaluated adverse events, serious adverse events, immunogenicity, vital signs, clinical laboratory assessments, physical and neurological examinations, electrocardiograms, and changes in weight. Secondary assessments included serum pharmacokinetics, AP-101 concentrations in cerebrospinal fluid, and the neurofilament biomarkers phosphorylated neurofilament heavy chain (pNfH) and neurofilament light chain (NfL). Exploratory assessments included the ALS Functional Rating Scale-Revised, slow vital capacity, muscle strength, King's staging, survival and ventilation outcomes, quality of life, and cerebrospinal fluid total and misfolded SOD1.

03

Conditions studied

  • Amyotrophic Lateral Sclerosis

Keywords

  • Familial Amyotrophic Lateral Sclerosis
  • Sporadic Amyotrophic Lateral Sclerosis
04

Who can participate

The criteria were revised on the registry on Sep 30, 2026. See what changed

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • All participants must adhere to restrictions
  • Female participants of must adhere to contraception restrictions
  • Have possible, clinically probable, clinically probable-laboratory supported or definite familial or sporadic ALS in accordance with the El-Escorial criteria or who have a diagnosis of ALS as defined by the Gold Coast Criteria; progressive motor impairment documented by history or repeated clinical examination, preceded by normal motor development, and presence of upper and lower motor neuron dysfunction in at least 1 body region or lower motor neuron dysfunction in at least 2 body regions and investigations excluding other conditions
  • In familial ALS participants, a confirmed pathogenic superoxide dismutase 1 (SOD1) mutation
  • Onset of symptoms (i.e, weakness) within past 24 months prior to screening, at the time of obtaining
  • Have slow vital capacity (SVC) of greater than or equal to (> or =) 50 percentage (%) of predicted values. Participants with SVC of \<50% of predicted values may be permitted to enter the open-label extension, based on the opinion of the investigator
  • Absence of bilevel positive airway pressure (BiPAP)/proportional assist ventilation (PAV) > 4 hours for symptoms attributable to ALS. Use of a CPAP for pre-existing conditions will be allowed
  • If on riluzole, must be on a stable dose.
  • If on edaravone, must have completed 2 cycles and are expected to remain on the same dose throughout the study
  • Able to provide informed consent which includes compliance with the requirements and restrictions
  • Have venous access sufficient to allow for blood sampling
  • Have clinical laboratory test results within the normal reference range for the population or study site, or results with acceptable deviations that are judged to be not by the investigator

Exclusion criteria

Exclusion Criteria:

  • Have participated or currently participating in another clinical trial within 5 half-lives of baseline (Day 1)
  • Have undergone a tracheostomy for ALS symptoms
  • Are on nasal intermittent positive pressure ventilation (NIPPV) >4 hours per day for the treatment of ALS related symptoms
  • Have other causes of neuromuscular weakness
  • Have cognitive impairment, severe disease in the cardiovascular, hematological, renal system, neurodegenerative disease, pulmonary disorder, or psychiatric illness
  • Pregnant or nursing women
  • Have been exposed to any antisense treatment targeting SOD1 within 6 months of the baseline visit
  • Have undergone stem cell therapy
Terms in these criteria, in plain language(4)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Double (Participant, Investigator)
Enrollment
73 participants (actual)

Study arms

  • Experimental
    AP-101

    AP-101 is administered by intravenous infusion (IV).

    Drug: AP-101

  • Placebo comparator
    Placebo

    Placebo is administered by intravenous infusion (IV).

    Drug: Placebo

Interventions

  • DrugAP-101

    Participants receive AP-101 by intravenous infusion (IV).

  • DrugPlacebo

    Participants receive placebo by intravenous infusion (IV).

06

What researchers measure

Primary outcomes

  1. Participants With Treatment-Emergent Adverse Events (TEAE) and Treatment-Emergent Serious Adverse Events (TESAE) During the Double-Blind Period

    Treatment-emergent adverse events were adverse events that began or worsened after the first dose of randomized study treatment during the double-blind period. Treatment-emergent serious adverse events met the protocol-defined criteria for seriousness. Participants experiencing more than one event within a category were counted once in that category. Results are presented separately for the sporadic ALS and SOD1-associated ALS cohorts.

    Time frame: From the first dose through the 21-day follow-up after Week 24, approximately 27 weeks

  2. Number of Participants With Abnormalities in Vital Signs, Clinical Laboratory Assessments, Physical and Neurological Examinations, and Electrocardiograms

    Number of participants with at least one abnormality in vital signs, clinical laboratory assessments, physical examinations, neurological examinations, or electrocardiograms during the double-blind period. Participants could be included in more than one category; therefore, categories were not mutually exclusive. Results are presented separately for the sporadic ALS and SOD1-associated ALS cohorts.

    Time frame: From the first dose through the 21-day follow-up after Week 24, approximately 27 weeks

  3. Participants With Treatment-Emergent Anti-Drug Antibodies (ADAs) During the Double-Blind Period

    Serum samples were assessed for anti-drug antibodies to AP-101. Participants were evaluable for treatment-emergent anti-drug antibodies if they had at least one non-missing baseline result and at least one non-missing post-baseline result. One participant was anti-drug-antibody positive at baseline and subsequently tested negative; baseline positivity was not classified as treatment-emergent. Results are presented separately for the sporadic ALS and SOD1-associated ALS cohorts. ADA testing was not assessed in placebo participants.

    Time frame: From baseline through the 21-day follow-up after Week 24, approximately 27 weeks

Secondary outcomes

  1. Model-Derived Elimination Half-Life of AP-101 in Serum

    The individual elimination half-life of AP-101 was estimated using empirical Bayes estimates from the final two-compartment population pharmacokinetic model. The model used pooled serum AP-101 concentration data from studies AP101-01 and AP101-02. This outcome summarizes participants from AP101-02 who were included in the final population pharmacokinetic model.

    Time frame: From the first AP-101 dose through 16 weeks after the final AP-101 dose, up to approximately 64 weeks

  2. Model-Derived Area Under the Serum AP-101 Concentration-Time Curve

    Individual AP-101 exposure was estimated using empirical Bayes estimates from the final two-compartment population pharmacokinetic model. Area under the concentration-time curve during the dosing interval was estimated following the second active AP-101 dose and at steady state. This outcome summarizes AP101-02 participants included in the final population pharmacokinetic model.

    Time frame: AUC following the second active dose: Day 2 through Day 22; AUC at steady state: the 21-day dosing interval following the participant's final active AP-101 dose, which occurred up to approximately Week 48 of the study

  3. Model-Derived Maximum Serum AP-101 Concentration

    Individual maximum serum AP-101 concentrations were estimated using empirical Bayes estimates from the final two-compartment population pharmacokinetic model. Maximum concentration was estimated following the second active AP-101 dose and at steady state. This outcome summarizes AP101-02 participants included in the final population pharmacokinetic model.

    Time frame: Cmax following the second active dose: Day 2 through Day 22; Cmax at steady state: during the 21-day dosing interval following the participant's final active AP-101 dose, which occurred up to approximately Week 48 of the study.

  4. AP-101 Concentration in Cerebrospinal Fluid During the Double-Blind Period

    AP-101 concentrations were measured in cerebrospinal fluid to assess central nervous system exposure after repeated intravenous dosing. Samples were collected at Week 12 and Week 24 of the double-blind period and summarized by ALS cohort and visit among participants with quantifiable CSF AP-101 concentrations. Actual concentrations were reported rather than change from baseline because nearly all baseline concentrations were below the limit of quantitation.

    Time frame: Week 12 and Week 24 of the double-blind period

  5. Change From Baseline in Cerebrospinal Fluid Phosphorylated Neurofilament Heavy Chain (pNfH) During the Double-Blind Period

    Phosphorylated neurofilament heavy chain (pNfH) concentrations were measured in cerebrospinal fluid at baseline, Week 12, and Week 24. Results represent the mean change from baseline and are presented separately for the sporadic ALS and SOD1-ALS cohorts. Negative values indicate a decrease from baseline.

    Time frame: Baseline to Week 24 of the double-blind period

  6. Change From Baseline in Serum Neurofilament Light Chain During the Double-Blind Period and 21-Day Follow-up

    Neurofilament light chain (NfL) concentrations were measured in serum at baseline, Week 12, Week 24, and the 21-day follow-up after completion of double-blind treatment. Results represent the mean change from baseline and are presented separately for the sporadic ALS and SOD1-ALS cohorts. Negative values indicate a decrease from baseline.

    Time frame: Baseline through the 21-day follow-up after Week 24, approximately 27 weeks

07

Results

Posted Sep 30, 2026
Limitations and caveats
This Phase 2a study was designed primarily to evaluate safety and tolerability. Pharmacokinetics and the neurofilament biomarkers; phosphorylated neurofilament heavy chain (pNfH) and neurofilament light chain (NfL) were secondary endpoints. Clinical efficacy measures and other biomarkers were exploratory. Interpretation may be limited by small cohort sizes, no adjustment for multiplicity, and crossover and attrition in the optional open-label extension.

Participant flow

The study was conducted at 14 study centers; 13 centers enrolled participants. A total of 83 participants were screened and 73 were randomized and received study treatment.

Double-Blind Period (24 Weeks)
Participant flow — Double-Blind Period (24 Weeks)
MilestoneSporadic ALS - AP-101Sporadic ALS - PlaceboSOD1-Associated ALS - AP-101SOD1-Associated ALS - Placebo
Started3418147
Completed2315133
Not completed11314
Withdrew: Withdrawal by subject7010
Withdrew: Adverse event2100
Withdrew: Death0001
Withdrew: Physician decision0001
Withdrew: Protocol violation0101
Withdrew: Enrollment in another clinical study0001
Withdrew: At ole week 3, svc was 41%, niv use was >6 hours/night, and orthopnea had developed.1000
Withdrew: Did not complete all protocol specified follow up assessments1000
Withdrew: Incorrect enrollment in the study0100
Open-Label Extension (24 Weeks)
Participant flow — Open-Label Extension (24 Weeks)
MilestoneSporadic ALS - AP-101Sporadic ALS - PlaceboSOD1-Associated ALS - AP-101SOD1-Associated ALS - Placebo
Started2315133
Completed1911122
Not completed4411
Withdrew: Withdrawal by subject3210
Withdrew: Adverse event1201

Outcome measures

PrimaryParticipants With Treatment-Emergent Adverse Events (TEAE) and Treatment-Emergent Serious Adverse Events (TESAE) During the Double-Blind Period

Treatment-emergent adverse events were adverse events that began or worsened after the first dose of randomized study treatment during the double-blind period. Treatment-emergent serious adverse events met the protocol-defined criteria for seriousness. Participants experiencing more than one event within a category were counted once in that category. Results are presented separately for the sporadic ALS and SOD1-associated ALS cohorts.

Time frame:
From the first dose through the 21-day follow-up after Week 24, approximately 27 weeks
Reported as:
Number · participants
Participants With Treatment-Emergent Adverse Events (TEAE) and Treatment-Emergent Serious Adverse Events (TESAE) During the Double-Blind Period
participantsSporadic ALS - AP-101Sporadic ALS - PlaceboSOD1-Associated ALS - AP-101SOD1-Associated ALS - Placebo
At Least One TEAE3317136
At Least One TESAE6403
PrimaryNumber of Participants With Abnormalities in Vital Signs, Clinical Laboratory Assessments, Physical and Neurological Examinations, and Electrocardiograms

Number of participants with at least one abnormality in vital signs, clinical laboratory assessments, physical examinations, neurological examinations, or electrocardiograms during the double-blind period. Participants could be included in more than one category; therefore, categories were not mutually exclusive. Results are presented separately for the sporadic ALS and SOD1-associated ALS cohorts.

Time frame:
From the first dose through the 21-day follow-up after Week 24, approximately 27 weeks
Reported as:
Number · participants
Number of Participants With Abnormalities in Vital Signs, Clinical Laboratory Assessments, Physical and Neurological Examinations, and Electrocardiograms
participantsSporadic ALS - AP-101Sporadic ALS - PlaceboSOD1-Associated ALS - AP-101SOD1-Associated ALS - Placebo
Vital Sign Abnormality231243
Clinical Laboratory Assessment Abnormality3310
Physical Examination Abnormality3418147
Neurological Examination Abnormality3418147
Electrocardiogram Abnormality261443
Any of the Above Abnormalities3418147
PrimaryParticipants With Treatment-Emergent Anti-Drug Antibodies (ADAs) During the Double-Blind Period

Serum samples were assessed for anti-drug antibodies to AP-101. Participants were evaluable for treatment-emergent anti-drug antibodies if they had at least one non-missing baseline result and at least one non-missing post-baseline result. One participant was anti-drug-antibody positive at baseline and subsequently tested negative; baseline positivity was not classified as treatment-emergent. Results are presented separately for the sporadic ALS and SOD1-associated ALS cohorts. ADA testing was not assessed in placebo participants.

Time frame:
From baseline through the 21-day follow-up after Week 24, approximately 27 weeks
Reported as:
Number · participants
Participants With Treatment-Emergent Anti-Drug Antibodies (ADAs) During the Double-Blind Period
participantsSporadic ALS - AP-101SOD1-Associated ALS - AP-101
Participants With Treatment-Emergent Anti-Drug Antibodies (ADAs) During the Double-Blind Period00
SecondaryModel-Derived Elimination Half-Life of AP-101 in Serum

The individual elimination half-life of AP-101 was estimated using empirical Bayes estimates from the final two-compartment population pharmacokinetic model. The model used pooled serum AP-101 concentration data from studies AP101-01 and AP101-02. This outcome summarizes participants from AP101-02 who were included in the final population pharmacokinetic model.

Time frame:
From the first AP-101 dose through 16 weeks after the final AP-101 dose, up to approximately 64 weeks
Reported as:
Mean · hours
Model-Derived Elimination Half-Life of AP-101 in Serum
hoursAll Participants Receiving AP-101
Model-Derived Elimination Half-Life of AP-101 in Serum515.77 ± 133.80
SecondaryModel-Derived Area Under the Serum AP-101 Concentration-Time Curve

Individual AP-101 exposure was estimated using empirical Bayes estimates from the final two-compartment population pharmacokinetic model. Area under the concentration-time curve during the dosing interval was estimated following the second active AP-101 dose and at steady state. This outcome summarizes AP101-02 participants included in the final population pharmacokinetic model.

Time frame:
AUC following the second active dose: Day 2 through Day 22; AUC at steady state: the 21-day dosing interval following the participant's final active AP-101 dose, which occurred up to approximately Week 48 of the study
Reported as:
Mean · µg·h/mL
Model-Derived Area Under the Serum AP-101 Concentration-Time Curve
µg·h/mLAll Participants Receiving AP-101
AUC During the Dosing Interval Following the Second Active Dose (Day 2 through Day 22)125585.05 ± 35634.55
AUC During the 21-day Dosing Interval at Steady State (approximately Week 48 of the study)203818.06 ± 69764.09
SecondaryModel-Derived Maximum Serum AP-101 Concentration

Individual maximum serum AP-101 concentrations were estimated using empirical Bayes estimates from the final two-compartment population pharmacokinetic model. Maximum concentration was estimated following the second active AP-101 dose and at steady state. This outcome summarizes AP101-02 participants included in the final population pharmacokinetic model.

Time frame:
Cmax following the second active dose: Day 2 through Day 22; Cmax at steady state: during the 21-day dosing interval following the participant's final active AP-101 dose, which occurred up to approximately Week 48 of the study.
Reported as:
Mean · µg/mL
Model-Derived Maximum Serum AP-101 Concentration
µg/mLAll Participants Receiving AP-101
Maximum Serum Concentration (Cmax) Following the Second Active Dose (Day 2 through Day 22)930.84 ± 161.78
Maximum Serum Concentration (Cmax) at Steady State (approximately Week 48 of the study)1058.09 ± 200.94
SecondaryAP-101 Concentration in Cerebrospinal Fluid During the Double-Blind Period

AP-101 concentrations were measured in cerebrospinal fluid to assess central nervous system exposure after repeated intravenous dosing. Samples were collected at Week 12 and Week 24 of the double-blind period and summarized by ALS cohort and visit among participants with quantifiable CSF AP-101 concentrations. Actual concentrations were reported rather than change from baseline because nearly all baseline concentrations were below the limit of quantitation.

Time frame:
Week 12 and Week 24 of the double-blind period
Reported as:
Mean · micrograms per milliliter
AP-101 Concentration in Cerebrospinal Fluid During the Double-Blind Period
micrograms per milliliterParticipants With Quantifiable CSF AP-101 Concentrations
Sporadic ALS: Week 121.23 ± 0.76
Sporadic ALS: Week 241.18 ± 0.70
SOD1-ALS: Week 120.92 ± 0.45
SOD1-ALS: Week 241.08 ± 0.43
SecondaryChange From Baseline in Cerebrospinal Fluid Phosphorylated Neurofilament Heavy Chain (pNfH) During the Double-Blind Period

Phosphorylated neurofilament heavy chain (pNfH) concentrations were measured in cerebrospinal fluid at baseline, Week 12, and Week 24. Results represent the mean change from baseline and are presented separately for the sporadic ALS and SOD1-ALS cohorts. Negative values indicate a decrease from baseline.

Time frame:
Baseline to Week 24 of the double-blind period
Reported as:
Mean · ng/mL
Change From Baseline in Cerebrospinal Fluid Phosphorylated Neurofilament Heavy Chain (pNfH) During the Double-Blind Period
ng/mLAP-101Placebo
Sporadic ALS: Week 12 Change From Baseline-0.249 ± 0.59230.105 ± 0.4137
Sporadic ALS: Week 24 Change From Baseline0.132 ± 1.34060.236 ± 0.5716
SOD1-ALS: Week 12 Change From Baseline-0.379 ± 0.9801-0.595 ± 1.1599
SOD1-ALS: Week 24Change From Baseline-0.115 ± 1.23420.360 ± 0.9057
SecondaryChange From Baseline in Serum Neurofilament Light Chain During the Double-Blind Period and 21-Day Follow-up

Neurofilament light chain (NfL) concentrations were measured in serum at baseline, Week 12, Week 24, and the 21-day follow-up after completion of double-blind treatment. Results represent the mean change from baseline and are presented separately for the sporadic ALS and SOD1-ALS cohorts. Negative values indicate a decrease from baseline.

Time frame:
Baseline through the 21-day follow-up after Week 24, approximately 27 weeks
Reported as:
Mean · pg/mL
Change From Baseline in Serum Neurofilament Light Chain During the Double-Blind Period and 21-Day Follow-up
pg/mLAP-101Placebo
Sporadic ALS: Week 12 Change From Baseline-3.07 ± 18.046-6.01 ± 33.720
Sporadic ALS: Week 24 Change From Baseline18.00 ± 56.691-3.42 ± 41.658
Sporadic ALS: 21-Day Follow-up Change From Baseline-6.51 ± 15.1931.44 ± 27.570
SOD1-ALS: Week 12 Change From Baseline-3.23 ± 9.780-3.36 ± 19.135
SOD1-ALS: Week 24 Change From Baseline-1.48 ± 9.11015.35 ± 66.290
SOD1-ALS: 21-Day Follow-up Change From Baseline3.30 ± 12.217-22.00 ± 18.385

Adverse events

Collected over From the first dose of randomized study treatment through 16 weeks after the participant's final study dose, up to approximately 64 weeks. Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
AP-101 Exposure9/66 (13.6%)19/66 (28.8%)64/66 (97%)
Placebo Exposure1/25 (4%)7/25 (28%)23/25 (92%)
Most frequent serious events
Showing 10 of 17
Most frequent serious events
EventAP-101 ExposurePlacebo Exposure
DysphagiaGastrointestinal disorders5/663/25
PneumoniaInfections and infestations2/662/25
Respiratory failureRespiratory, thoracic and mediastinal disorders3/661/25
Pneumonia aspirationInfections and infestations3/661/25
Acute respiratory failureRespiratory, thoracic and mediastinal disorders0/661/25
Pneumonia pneumococcalInfections and infestations0/661/25
ConcussionInjury, poisoning and procedural complications0/661/25
Respiratory distressRespiratory, thoracic and mediastinal disorders2/660/25
DyspneaRespiratory, thoracic and mediastinal disorders1/660/25
HypoventilationRespiratory, thoracic and mediastinal disorders1/660/25
Most frequent other events
Showing 10 of 34
Most frequent other events
EventAP-101 ExposurePlacebo Exposure
FallInjury, poisoning and procedural complications25/6611/25
NasopharyngitisInfections and infestations23/665/25
DiarrhoeaGastrointestinal disorders11/660/25
HeadacheNervous system disorders11/663/25
COVID-19Infections and infestations9/662/25
RashSkin and subcutaneous tissue disorders8/663/25
RhinitisInfections and infestations0/663/25
ConstipationGastrointestinal disorders5/663/25
ContusionInjury, poisoning and procedural complications4/663/25
Weight decreasedInvestigations3/663/25

Baseline characteristics

Safety Population: all randomized participants who received at least one dose of study treatment. Baseline characteristics are presented separately by ALS cohort and randomized treatment assignment.

Age, Continuous
Age, Continuous(years)Sporadic ALS - AP-101Sporadic ALS - PlaceboSOD1-Associated ALS - AP-101SOD1-Associated ALS - PlaceboTotal
Mean57.8 ± 9.2659.7 ± 10.8245.6 ± 13.3448.6 ± 8.6655.05 ± 11.65
Sex: Female, Male
Sex: Female, Male(Participants)Sporadic ALS - AP-101Sporadic ALS - PlaceboSOD1-Associated ALS - AP-101SOD1-Associated ALS - PlaceboTotal
Female945321
Male25149452
Ethnicity (NIH/OMB)
Ethnicity (NIH/OMB)(Participants)Sporadic ALS - AP-101Sporadic ALS - PlaceboSOD1-Associated ALS - AP-101SOD1-Associated ALS - PlaceboTotal
Hispanic or Latino20002
Not Hispanic or Latino321814771
Unknown or Not Reported00000
Race (NIH/OMB)
Race (NIH/OMB)(Participants)Sporadic ALS - AP-101Sporadic ALS - PlaceboSOD1-Associated ALS - AP-101SOD1-Associated ALS - PlaceboTotal
American Indian or Alaska Native00000
Asian841114
Native Hawaiian or Other Pacific Islander00000
Black or African American00000
White261413659
More than one race00000
Unknown or Not Reported00000
Body Mass Index
Body Mass Index(kg/m²)Sporadic ALS - AP-101Sporadic ALS - PlaceboSOD1-Associated ALS - AP-101SOD1-Associated ALS - PlaceboTotal
Mean26.132 ± 4.028825.111 ± 3.038627.829 ± 5.855526.600 ± 5.770326.251 ± 4.406
Months Since ALS Diagnosis
Months Since ALS Diagnosis(months)Sporadic ALS - AP-101Sporadic ALS - PlaceboSOD1-Associated ALS - AP-101SOD1-Associated ALS - PlaceboTotal
Mean6.390 ± 5.24045.206 ± 3.34293.826 ± 3.50484.281 ± 2.58285.404 ± 4.367
Amyotrophic Lateral Sclerosis Functional Rating Scale-Revised (ALSFRS-R) Total Score
Amyotrophic Lateral Sclerosis Functional Rating Scale-Revised (ALSFRS-R) Total Score(point based scores on a scale)Sporadic ALS - AP-101Sporadic ALS - PlaceboSOD1-Associated ALS - AP-101SOD1-Associated ALS - PlaceboTotal
Mean39.3 ± 3.7738.7 ± 5.3140.9 ± 5.1637.7 ± 4.4639.31 ± 4.52
Riluzole Use
Riluzole Use(Participants)Sporadic ALS - AP-101Sporadic ALS - PlaceboSOD1-Associated ALS - AP-101SOD1-Associated ALS - PlaceboTotal
Count of participants341812771

5 further baseline measures are reported on the registry.

08

Study locations

13 sites
  • UC San Diego, ACTRI
    La Jolla, California 92037, United States
  • Department of Neurology, University Hospitals
    Leuven, 3000, Belgium
  • ALS clinic at the Kaye Edmonton Clinic, University of Alberta
    Edmonton, Alberta AB T6G 1Z1, Canada
  • London Health Sciences Centre - Victoria Hospital
    London, Ontario ON N6A 5W9, Canada
  • ALS Research Sunnybrook Health Sciences Centre
    Toronto, Ontario M4N 3M5, Canada
  • Montreal Neurological Institute and Hospital / Dr Genge
    Montreal, Quebec H3A 2B4, Canada
  • Charité
    Berlin, 13353, Germany
  • Deutsches Zentrum für Neurodegenerative Erkrankungen e.V. (DZNE)
    Bonn, 53127, Germany
  • Hannover Medical School
    Hanover, 30625, Germany
  • Ulm University Hospital
    Ulm, 89081, Germany
  • Hanyang University Medical Center
    Seoul, 04763, South Korea
  • Studieenheten Akademiskt specialistcentrum, SLSO
    Stockholm, 113 61, Sweden
  • Norrlands universitetssjukhus/ University Hospital of Northern Sweden (NUS)
    Umeå, SE- 901 85, Sweden
09

References and documents

Study documents

PDFs hosted by the registry, ClinicalTrials.gov.

10

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Sep 2021 to primary completion in Aug 2025, 47 months.

Results were first posted in Sep 2026, 1 year 1 month after primary completion.

Of 36 industry-sponsored phase 2 interventional studies under Amyotrophic Lateral Sclerosis, half reached primary completion within 21 months of starting (the median), counting those still running; a quarter within 15 and three quarters within 35. This study's 47 months is above that.

Counting every sponsor, half of 73 studies reached it within 24 months; a quarter within 16 and three quarters within 35.

How these figures are worked out, and which studies are left out of them.

Registered
Sep 1, 2021
First posted
Sep 9, 2021
StartActual
Sep 2, 2021
Primary completionActual
Aug 13, 2025
CompletionActual
Aug 13, 2025
Results first posted
Sep 30, 2026
Last update
Sep 30, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Results
Results posted
posted Sep 30, 2026
Sites
5 sites added, 5 sites removed
Show 5 added (3 Germany, 1 South Korea, 1 Sweden)
  • Charité · Berlin, Germany
  • Hannover Medical School · Hanover, Germany
  • Ulm University Hospital · Ulm, Germany
  • Hanyang University Medical Center · Seoul, South Korea
  • Studieenheten Akademiskt specialistcentrum, SLSO · Stockholm, Sweden
Show 5 removed
  • Hannover Medical School · Hanover, Germany
  • Charité · Berlin, Germany
  • Ulm University Hospital · Ulm, Germany
  • Hanyang University Medical Center · Seoul, South Korea
  • Studieenheten Akademiskt specialistcentrum, SLSO · Stockholm, Sweden
Sep 30, 2026
Eligibility
1 exclusion criterion edited
What changed in the criteria
Exclusion criteria
  • EditedHave participated or currently participating in another clinical trial within 12 weeks5 half-lives of baseline (Day 1)
Sep 30, 2026
Primary outcomes
1 edited, 2 added, 1 removed
What changed in the outcomes
  • EditedNumber of Participants withWith Abnormalities in Vital Signs, Clinical Laboratory Assessments, Physical and Neurological Examinations, and Electrocardiograms (ECGs)Time frame: From start of the study up to Week 51 → From the first dose through the 21-day follow-up after Week 24, approximately 27 weeks
  • AddedParticipants With Treatment-Emergent Adverse Events (TEAE) and Treatment-Emergent Serious Adverse Events (TESAE) During the Double-Blind PeriodTime frame: From the first dose through the 21-day follow-up after Week 24, approximately 27 weeks
  • AddedParticipants With Treatment-Emergent Anti-Drug Antibodies (ADAs) During the Double-Blind PeriodTime frame: From baseline through the 21-day follow-up after Week 24, approximately 27 weeks
  • RemovedNumber of Participants With Adverse Events (AEs) and Serious AEs (SAEs)Time frame: From start of the study up to Week 51
Sep 30, 2026
Documents
Secondary outcomes
2 edited, 4 added, 4 removed
What changed in the outcomes
  • EditedModel-Derived Elimination halfHalf-life (t1/2)Life of AP-101 in SerumTime frame: Predose up to Week 51 → From the first AP-101 dose through 16 weeks after the final AP-101 dose, up to approximately 64 weeks
  • EditedModel-Derived Area Under the DrugSerum AP-101 Concentration-Time Curve (AUC)Time frame: Predose up to Week 51 → AUC following the second active dose: Day 2 through Day 22; AUC at steady state: the 21-day dosing interval following the participant's final active AP-101 dose, which occurred up to approximately Week 48 of the study
  • AddedModel-Derived Maximum Serum AP-101 ConcentrationTime frame: Cmax following the second active dose: Day 2 through Day 22; Cmax at steady state: during the 21-day dosing interval following the participant's final active AP-101 dose, which occurred up to approximately Week 48 of the study.
  • AddedAP-101 Concentration in Cerebrospinal Fluid During the Double-Blind PeriodTime frame: Week 12 and Week 24 of the double-blind period
  • AddedChange From Baseline in Cerebrospinal Fluid Phosphorylated Neurofilament Heavy Chain (pNfH) During the Double-Blind PeriodTime frame: Baseline to Week 24 of the double-blind period
  • AddedChange From Baseline in Serum Neurofilament Light Chain During the Double-Blind Period and 21-Day Follow-upTime frame: Baseline through the 21-day follow-up after Week 24, approximately 27 weeks
  • RemovedConcentration at End of Infusion (Cat EOI)Time frame: Week 24
  • RemovedChange From Baseline in AP-101 Levels in the Cerebrospinal Fluid (CSF) up to Week 24Time frame: Baseline, up to Week 24
  • RemovedChange From Baseline in Neurofilament Light Chain and Phospho-Neurofilament Heavy Chain Levels in the Cerebrospinal Fluid (CSF) up to Week 51Time frame: Baseline, up to Week 51
  • RemovedChange From Baseline in Neurofilament Light Chain and Phospho-Neurofilament Heavy Chain Levels in Plasma up to Week 51Time frame: Baseline, up to Week 51
Sep 30, 2026
Title
A Study to Evaluate, Safety, Tolerability, Pharmacodynamic (PD) Markers and Pharmacokinetics (PK) of AP-101 in Participants With Amyotrophic Lateral Sclerosis (ALS)
Sep 30, 2026
Show all 1 update
  1. Sep 30, 2026
    Results posted
    5 sites added, 5 sites removed
    Show 5 added (3 Germany, 1 South Korea, 1 Sweden)
    • Charité · Berlin, Germany
    • Hannover Medical School · Hanover, Germany
    • Ulm University Hospital · Ulm, Germany
    • Hanyang University Medical Center · Seoul, South Korea
    • Studieenheten Akademiskt specialistcentrum, SLSO · Stockholm, Sweden
    Show 5 removed
    • Hannover Medical School · Hanover, Germany
    • Charité · Berlin, Germany
    • Ulm University Hospital · Ulm, Germany
    • Hanyang University Medical Center · Seoul, South Korea
    • Studieenheten Akademiskt specialistcentrum, SLSO · Stockholm, Sweden
    Eligibility 1 exclusion criterion edited
    What changed in the criteria
    Exclusion criteria
    • EditedHave participated or currently participating in another clinical trial within 12 weeks5 half-lives of baseline (Day 1)
    Primary outcomes 1 edited, 2 added, 1 removed
    What changed in the outcomes
    • EditedNumber of Participants withWith Abnormalities in Vital Signs, Clinical Laboratory Assessments, Physical and Neurological Examinations, and Electrocardiograms (ECGs)Time frame: From start of the study up to Week 51 → From the first dose through the 21-day follow-up after Week 24, approximately 27 weeks
    • AddedParticipants With Treatment-Emergent Adverse Events (TEAE) and Treatment-Emergent Serious Adverse Events (TESAE) During the Double-Blind PeriodTime frame: From the first dose through the 21-day follow-up after Week 24, approximately 27 weeks
    • AddedParticipants With Treatment-Emergent Anti-Drug Antibodies (ADAs) During the Double-Blind PeriodTime frame: From baseline through the 21-day follow-up after Week 24, approximately 27 weeks
    • RemovedNumber of Participants With Adverse Events (AEs) and Serious AEs (SAEs)Time frame: From start of the study up to Week 51
    Secondary outcomes 2 edited, 4 added, 4 removed
    What changed in the outcomes
    • EditedModel-Derived Elimination halfHalf-life (t1/2)Life of AP-101 in SerumTime frame: Predose up to Week 51 → From the first AP-101 dose through 16 weeks after the final AP-101 dose, up to approximately 64 weeks
    • EditedModel-Derived Area Under the DrugSerum AP-101 Concentration-Time Curve (AUC)Time frame: Predose up to Week 51 → AUC following the second active dose: Day 2 through Day 22; AUC at steady state: the 21-day dosing interval following the participant's final active AP-101 dose, which occurred up to approximately Week 48 of the study
    • AddedModel-Derived Maximum Serum AP-101 ConcentrationTime frame: Cmax following the second active dose: Day 2 through Day 22; Cmax at steady state: during the 21-day dosing interval following the participant's final active AP-101 dose, which occurred up to approximately Week 48 of the study.
    • AddedAP-101 Concentration in Cerebrospinal Fluid During the Double-Blind PeriodTime frame: Week 12 and Week 24 of the double-blind period
    • AddedChange From Baseline in Cerebrospinal Fluid Phosphorylated Neurofilament Heavy Chain (pNfH) During the Double-Blind PeriodTime frame: Baseline to Week 24 of the double-blind period
    • AddedChange From Baseline in Serum Neurofilament Light Chain During the Double-Blind Period and 21-Day Follow-upTime frame: Baseline through the 21-day follow-up after Week 24, approximately 27 weeks
    • RemovedConcentration at End of Infusion (Cat EOI)Time frame: Week 24
    • RemovedChange From Baseline in AP-101 Levels in the Cerebrospinal Fluid (CSF) up to Week 24Time frame: Baseline, up to Week 24
    • RemovedChange From Baseline in Neurofilament Light Chain and Phospho-Neurofilament Heavy Chain Levels in the Cerebrospinal Fluid (CSF) up to Week 51Time frame: Baseline, up to Week 51
    • RemovedChange From Baseline in Neurofilament Light Chain and Phospho-Neurofilament Heavy Chain Levels in Plasma up to Week 51Time frame: Baseline, up to Week 51
    Title A Study to Evaluate, Safety, Tolerability, Pharmacodynamic (PD) Markers and Pharmacokinetics (PK) of AP-101 in Participants With Amyotrophic Lateral Sclerosis (ALS)
    + 6 other changes: verification date, oversight details, description, arm descriptions, contact details and index terms

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

11

Registry details

Key details

Study ID
NCT05039099
Lead sponsor
AL-S Pharma
Responsible party
Sponsor
First posted
Sep 9, 2021
Start date
Sep 2, 2021
Primary completion
Aug 13, 2025
Completion
Aug 13, 2025
Results posted
Sep 30, 2026
Last update
Sep 30, 2026

Study contacts

Study Director
study director · AL-S Pharma AG

Oversight

Data monitoring committee
Yes
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Sep 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Episalvan

Start the discussion